SCHEMBL23833638

SCHEMBL23833638

Cc1cc(Cl)ncc1N1CCCC1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.51
▸ LMNA P02545 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ AKR1C3 P42330 1/20 0.40
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ FFAR1 O14842 4/20 0.38
▸ FFAR4 Q5NUL3 3/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ PKM P14618 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ BRD9 Q9H8M2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MGAT2 Q10469 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30094610 1.00 HSD17B10 (0.51) HSD17B10LMNAL3MBTL1AKR1C3CYP3A4
SCHEMBL30094589 0.78 HSD17B10 (0.51) HSD17B10LMNAL3MBTL1AKR1C3CYP3A4
SCHEMBL23833533 0.78 HSD17B10 (0.51) HSD17B10LMNAL3MBTL1AKR1C3CYP3A4
SCHEMBL22575305 0.78 ALOX5AP (0.48) HSD17B10CNR2MGAT2
SCHEMBL22575309 0.77 PRKAB2 (0.45) HSD17B10LMNACNR2PKMBRD9
SCHEMBL19819310 0.76 CNR2 (0.44) HSD17B10LMNACYP3A4CYP2C9CNR2
SCHEMBL29856816 0.76 CNR2 (0.44) HSD17B10LMNACYP3A4CYP2C9CNR2
SCHEMBL11179443 0.74 HSD17B10 (0.60) HSD17B10LMNAL3MBTL1AKR1C3CYP3A4
SCHEMBL16574014 0.72 HSD17B10 (0.54) HSD17B10LMNAL3MBTL1CYP3A4CYP2C9
SCHEMBL24388818 0.72 HSD17B10 (0.50) HSD17B10LMNAL3MBTL1AKR1C3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 — — EP disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 — — CN disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 HSD17B10 343/4885LMNA 4071/4885L3MBTL1 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback